With over two decades of experience at the intersection of science and clinical innovation, Dr. Dangerfield has led the development and implementation of advanced therapies across multiple therapeutic areas, including oncology, regenerative medicine, and healthy ageing. He has overseen the clinical integration of cell and gene therapies, biologics, and targeted delivery systems into functional medical protocols, aligning cutting-edge science with patient-centred care. His work spans the full translational pathway—from laboratory research and GMP manufacturing to regulatory strategy and international clinical deployment.

A skilled scientific communicator and leader, he has chaired international conferences, established expert working groups, and mentored PhD-level researchers in virology, gene therapy, and nanomedicine.